SK Bioscience has decided to invest 2.4 trillion won over the next five years. SK Bioscience announced on the 27th at 2:00 pm that it would announce its mid-to-long-term growth strategy to stock analysts and institutional investors.

According to the disclosure, SK bioscience will spend 2.4 trillion won over the five years from this year to 2027 to ▲secure overseas production bases, ▲expand sales of SKYBAX, a vaccine developed in-house, ▲do CDMO business, and ▲premium vaccine business. are going to invest

First of all, it secures a global production base that meets the environment and needs of each country around the world and creates various profit models to advance its assets. It pla